Dan Elwood

发表

Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine

D. Sack, S. Chakraborty, A. L. Bourgeois, 2021, EBioMedicine.

Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.

K. Subbarao, N. Hynes, K. Pierce, 2015, The Journal of infectious diseases.

A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.

B. Murphy, K. Subbarao, J. Lindow, 2013, The Journal of infectious diseases.

Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection

D. Sack, S. Chakraborty, A. L. Bourgeois, 2021, EBioMedicine.

The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers.

P. Wright, A. Pletnev, S. Whitehead, 2013, Vaccine.

A Single Dose of the DENV-1 Candidate Vaccine rDEN1Δ30 Is Strongly Immunogenic and Induces Resistance to a Second Dose in a Randomized Trial

B. Murphy, S. Whitehead, J. Blaney, 2011, PLoS neglected tropical diseases.

Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic.

B. Murphy, A. Durbin, A. Schmidt, 2011, The Journal of infectious diseases.

In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination

K. Subbarao, N. Hynes, K. Pierce, 2017, PLoS neglected tropical diseases.